Protara Therapeutics, Inc. Interest Expense
Protara Therapeutics, Inc. (TARA) reported Interest Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-09.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2022-03-09
- Protara Therapeutics, Inc. interest expense for the quarter ending 2014-12-31 was $13.00K, a 98.12% decline year-over-year.
- Protara Therapeutics, Inc. interest expense for the quarter ending 2014-09-30 was -$10.00K, a 105.85% decline year-over-year.
- Protara Therapeutics, Inc. interest expense for the quarter ending 2014-06-30 was $29.00K.
- Protara Therapeutics, Inc. interest expense for the quarter ending 2014-03-31 was $828.00K.
- Protara Therapeutics, Inc. interest expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Protara Therapeutics, Inc. interest expense for fiscal 2020 was $34.00K.
- Protara Therapeutics, Inc. interest expense for fiscal 2014 was $857.00K, a 0.46% decline from fiscal 2013.
- Protara Therapeutics, Inc. interest expense for fiscal 2013 was $861.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-09 | |||
| 2020-12-31 | $34.00K 10-K · filed 2022-03-09 | |||
| 2014-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-20 | $3.00K derived: sum of 2 quarters · filed 2015-03-20 | $32.00K derived: sum of 3 quarters · filed 2015-08-13 | $857.00K 10-K · filed 2015-03-20 |
| 2014-09-30 | -$10.00K 10-Q · filed 2014-11-25 | $19.00K derived: sum of 2 quarters · filed 2015-08-13 | $844.00K 10-Q · filed 2014-11-25 | $1.54M derived: sum of 4 quarters · filed 2015-08-13 |
| 2014-06-30 | $29.00K 10-Q · filed 2015-08-13 | $857.00K 10-Q · filed 2015-08-13 | $1.55M derived: sum of 3 quarters · filed 2015-08-13 | $1.72M derived: sum of 4 quarters · filed 2015-08-13 |
| 2014-03-31 | $828.00K 10-Q · filed 2015-05-13 | $1.52M derived: sum of 2 quarters · filed 2015-05-13 | $1.69M derived: sum of 3 quarters · filed 2015-05-13 | |
| 2013-12-31 | $693.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-20 | $864.00K derived: sum of 2 quarters · filed 2015-03-20 | $861.00K 10-K · filed 2015-03-20 | |
| 2013-09-30 | $171.00K 10-Q · filed 2014-11-25 | $168.00K 10-Q · filed 2014-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |